GOOD-IDES-02 (imlifidase) Phase 3 anti-GBM
Trial setup
- Trial: GOOD-IDES-02, global pivotal Phase 3 in anti-glomerular basement membrane (anti-GBM) disease. - Arms: imlifidase + standard of care vs standard of care. - Primary endpoint: renal function at 6 months, evaluated by eGFR (topline described as not met). - Key topline supportive readouts: dialysis-free status at 6 months and mean eGFR among dialysis-free patients (as reported).
Model leaderboard
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
No model results yet
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.